| 【Company Research】Bilibili (BILI US) – Factoring in epidemic impact |
| 【Company Research】Bank of Changsha (601577 CH) – FY21&1Q22 review: strong growth with good cost control |
| 【Company Research】Bank of Shanghai (601229 CH) – 1Q22 review: results in line, sufficient provision for headwind |
| 【Company Research】Tencent (700 HK) – Challenges yet over, but LT fundamentals intact |
| 【Company Research】China Construction Bank (939 HK) – 1Q22 review: results in line, propose to issue TLAC instruments in late FY22 |
| 【Company Research】SPDB (600000 CH) – FY21&1Q22 review: still waiting for the turning point |
| 【Company Research】PSBC (1658 HK) – 1Q22 review: strong growth beats our expectation |
| 【Company Research】CQRCB (3618 HK) – FY21 & 1Q22 review: results in line, asset quality improved |
| 【Company Research】Joinn Laboratories (6127 HK) – China-based DSA leader with global vision |
| 【Company Research】Ping An (2318 HK) – Stabilizing agency scale |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
